ES2174112T3 - Compuestos de vacuna para la gripe. - Google Patents

Compuestos de vacuna para la gripe.

Info

Publication number
ES2174112T3
ES2174112T3 ES96935149T ES96935149T ES2174112T3 ES 2174112 T3 ES2174112 T3 ES 2174112T3 ES 96935149 T ES96935149 T ES 96935149T ES 96935149 T ES96935149 T ES 96935149T ES 2174112 T3 ES2174112 T3 ES 2174112T3
Authority
ES
Spain
Prior art keywords
pct
flu
sec
date
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96935149T
Other languages
English (en)
Inventor
Steven N Chatfield
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd filed Critical West Pharmaceutical Services Drug Delivery and Clinical Research Center Ltd
Application granted granted Critical
Publication of ES2174112T3 publication Critical patent/ES2174112T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION PROPORCIONA UNA VACUNA CUYA PRESENTACION CONSTA DE UN PRIMER RECIPIENTE QUE CONTIENE UNA PREPARACION ANTIGENICA CON ANTIGENOS DEL VIRUS DE LA GRIPE Y UN SEGUNDO RECIPIENTE CON UNA CANTIDAD ADYUVANTE EFICAZ DE UN QUITOSAN. EL PREPARADO ANTIGENICO DEL PRIMER RECIPIENTE CONTIENE PREFERENTEMENTE LOS ANTIGENOS DEL VIRUS DE LA GRIPE HEMAGLUTININA Y NEURAMINIDASA.
ES96935149T 1995-11-01 1996-11-01 Compuestos de vacuna para la gripe. Expired - Lifetime ES2174112T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9522351.7A GB9522351D0 (en) 1995-11-01 1995-11-01 Vaccine compositions

Publications (1)

Publication Number Publication Date
ES2174112T3 true ES2174112T3 (es) 2002-11-01

Family

ID=10783215

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96935149T Expired - Lifetime ES2174112T3 (es) 1995-11-01 1996-11-01 Compuestos de vacuna para la gripe.

Country Status (18)

Country Link
US (1) US6136606A (es)
EP (1) EP0859632B1 (es)
JP (1) JP4010462B2 (es)
KR (1) KR100555687B1 (es)
CN (1) CN1201396A (es)
AT (1) ATE214615T1 (es)
AU (1) AU7322796A (es)
BR (1) BR9611218A (es)
CA (1) CA2236538C (es)
DE (1) DE69620001T2 (es)
DK (1) DK0859632T3 (es)
ES (1) ES2174112T3 (es)
GB (1) GB9522351D0 (es)
MX (1) MX9803290A (es)
NO (1) NO323555B1 (es)
NZ (1) NZ320488A (es)
PT (1) PT859632E (es)
WO (1) WO1997016208A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
GB9914412D0 (en) * 1999-06-22 1999-08-18 Worrall Eric E Method for the preservation of viruses,bacteria and biomolecules
US20020177614A1 (en) * 2001-03-23 2002-11-28 Merril Carl R. Methods for treating nuerodegenerative diseases including alzheimer's
EP1409009A1 (en) * 2001-06-15 2004-04-21 Nordic Vaccine Technology A/S Therapeutical vaccination
CN1253220C (zh) 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
AU2002346424A1 (en) * 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
WO2003086454A1 (en) * 2002-04-18 2003-10-23 Akzo Nobel N.V. Antigen-loaded chitosan microparticles for oral vaccination
WO2004098647A2 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins’ underexpression as markers of tumor metastasis
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
JP2007516968A (ja) * 2003-12-05 2007-06-28 ベクトン・ディキンソン・アンド・カンパニー 皮内コンパートメントにおける免疫応答を増強する方法、およびそれらの方法で有用な化合物
US20050129679A1 (en) 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
JPWO2006019183A1 (ja) * 2004-08-18 2008-05-08 国立大学法人徳島大学 粘膜免疫、その感作剤を用いる粘膜ワクチン及び予防接種システム
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
CN100425288C (zh) * 2005-01-28 2008-10-15 北京金迪克生物技术研究所 鼻腔喷雾型流感病毒灭活疫苗及其制备方法
CA2552596A1 (en) * 2005-08-09 2007-02-09 Solvay Pharmaceuticals B.V. Methods and systems for determining mid-value titers
CN101679974B (zh) 2007-03-27 2015-09-30 航道生物技术有限责任公司 包含抗体替代轻链序列的构建体和文库
JP2011516423A (ja) 2008-03-28 2011-05-26 シー レーン バイオテクノロジーズ， エルエルシー ウイルス抗原に対する中和分子
CA2761681A1 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
EP2308506A1 (en) * 2009-10-02 2011-04-13 Mucosis B.V. Adjuvanted intranasal vaccine formulations
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
GB202412729D0 (en) * 2024-08-30 2024-10-16 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Mucosal vaccine adjuvant

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
US5817753A (en) * 1985-12-04 1998-10-06 The Ohio State University Research Foundation Antigenic modification of polypeptides
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
DE59107006D1 (de) * 1990-04-25 1996-01-18 Hoechst Ag Pharmakologische Zubereitung, enthaltend Polyelektrolytkomplexe in mikropartikulärer Form und mindestens einen Wirkstoff.
US5169840A (en) * 1991-03-27 1992-12-08 Nobipols Forskningsstiftelse Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation
JP3109886B2 (ja) * 1991-12-13 2000-11-20 デンカ生研株式会社 経鼻接種用ワクチン
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
JPH06166635A (ja) * 1992-06-18 1994-06-14 San Five Kk 免疫アジュバント
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions

Also Published As

Publication number Publication date
PT859632E (pt) 2002-09-30
JP4010462B2 (ja) 2007-11-21
ATE214615T1 (de) 2002-04-15
BR9611218A (pt) 1999-05-25
NZ320488A (en) 2001-03-30
KR100555687B1 (ko) 2007-06-08
NO323555B1 (no) 2007-06-11
US6136606A (en) 2000-10-24
CA2236538C (en) 2011-05-10
KR19990067255A (ko) 1999-08-16
NO981963D0 (no) 1998-04-30
DE69620001D1 (de) 2002-04-25
NO981963L (no) 1998-06-30
JPH11515023A (ja) 1999-12-21
DE69620001T2 (de) 2002-11-21
CN1201396A (zh) 1998-12-09
EP0859632B1 (en) 2002-03-20
AU7322796A (en) 1997-05-22
WO1997016208A1 (en) 1997-05-09
EP0859632A1 (en) 1998-08-26
GB9522351D0 (en) 1996-01-03
DK0859632T3 (da) 2002-06-03
CA2236538A1 (en) 1997-05-09
MX9803290A (es) 1998-09-30

Similar Documents

Publication Publication Date Title
ES2174112T3 (es) Compuestos de vacuna para la gripe.
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
DE69818707D1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
EP0784485B8 (en) VACCINE COMPOSITIONS containing partially deacetylated chitin
AU2001295673A1 (en) Vaccine composition
BRPI9915545B8 (pt) composição de vacina, processo para preparação da mesma e kit compreendendo dois recipientes.
BR9812139A (pt) Vacina
IL150602A0 (en) Proteosome influenza vaccine
NZ510419A (en) A vaccine adjuvant that is an oil-in-water immunoslimulant emulsion
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
DE69634024D1 (de) Adjuvans für vitale Impfstoffe
DK0745388T3 (da) Mammalt vaccinepræparat omfattende squalen eller squalan, phospholipid og et overfladeaktivt stof som adjuvans
ATE195427T1 (de) Pertussistoxin enthaltender influenzaimpfstoff
WO1997005468A3 (en) A confirmatory serodiagnostic assay for infectious diseases

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 859632

Country of ref document: ES